Glutamate and the treatment of obsessive-compulsive disorder

Psychopharm Review

Volumn 45, Issue 5, 2010, Pages 33-39

  MacMaster, Frank P ^a   Rosenberg, David R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYCLOSERINE; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMIC ACID; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROTRANSMITTER; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN CORTEX; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; CORPUS STRIATUM; DRUG EFFICACY; DRUG ERUPTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; NEUROIMAGING; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PROTEIN EXPRESSION; REVIEW; THALAMUS;

EID: 78649361219     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.IDT.0000371058.38341.b3     Document Type: Review

References (34)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602.
2. Pauls DL, Alsobrook JP II, GoodmanW, et al. A family study of obsessive-compulsive disorder. Am J Psychiatry 1995;152(1):76-84.
3. Hanna GL. Demographic and clinical features of obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995;34(1):19-27.
4. van Grootheest DS, Cath DC, Beekman AT, et al. Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet 2005;8(5):450-458.
5. Stewart SE, Geller DA, Jenike M, et al. Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatr Scand 2004;110(1):4-13.
6. Hollander E, Kwon JH, Stein DJ, et al. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 1996;57(Suppl 8):3-6.
7. Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med 2004;350(3):259-265.
8. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessivecompulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004;292(16):1969-1976.
9. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13(7):266-271.
10. Rosenberg DR, Keshavan MS. A.E. Bennett Research Award. Toward a neurodevelopmental model of of obsessive-compulsive disorder. Biol Psychiatry 1998;43(9):623-640.
11. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J AmAcad Child Adolesc Psychiatry 2000; 39(9):1096-1103.
12. Bolton J,Moore GJ,MacMillan S, et al. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry 2001;40(8):903-906.
13. Benazon NR,Moore GJ, Rosenberg DR. Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. JAm Acad ChildAdolesc Psychiatry 2003;42(11):1279-1285.
14. Rosenberg DR, MirzaY, Russell A, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004;43(9):1146-1153.
15. Yucel M, Harrison BJ,Wood SJ, et al. Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder. Arch Gen Psychiatry 2007;64(8):946-955.
16. Whiteside SP, Port JD, Deacon BJ, et al. A magnetic resonance spectroscopy investigation of obsessivecompulsive disorder and anxiety. Psychiatry Res 2006;146(2):137-147.
17. Presti MF,Watson CJ, Kennedy RT, et al. Behaviorrelated alterations of striatal neurochemistry in a mouse model of stereotyped movement disorder. Pharmacol Biochem Behav 2004;77(3):501-507.
18. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30(9):1735-1740.
19. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessivecompulsive disorder. Arch Gen Psychiatry 2006;63(7):769-776.
20. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive- compulsive disorder. Arch Gen Psychiatry 2006;63(7):778-785.
21. Stewart SE, Fagerness JA, Platko J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive- compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144(8):1027-1033.
22. Autism Genome Project Consortium. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007; 39(3):319-28.
23. Arnold PD, MacMaster FP, Hanna GL, et al. Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder. Brain Imaging and Behav 2009;3:64-76.
24. Arnold PD, Rosenberg DR,Mundo E, et al.Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004;174(4):530-538.
25. Arnold PD, Macmaster FP, Richter MA, et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiatry Res 2009;172(2):136-139.
26. Coric V, Milanovic S,Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003;167(2):219-220.
27. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58(5):424-428.
28. Grant P, Lougee L, HirschtrittM, et al.An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007;17(6):761-767.
29. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184(2):254-6.
30. Wilhelm S, Buhlmann U,Tolin DF, et al.Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008;165(3):335-41.
31. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009;29(1):51-5.
32. Geller DA. Psychopharmacology of pediatric obsessive- compulsive disorder. In: Storch E, Geffken G, Murphy T, eds. Handbook of Child and Adolescent Obsessive-Compulsive Disorder. London: Lawrence ErlbaumAssociates; 2007:243-272.
33. Becquet D, Faudon M, Hery F. In vivo evidence for an inhibitory glutamatergic control of serotonin release in the cat caudate nucleus: involvement of GABA neurons. Brain Res 1990;519(1-2):82-88.
34. Sung NS, CrowleyWF Jr., Genel M, Salber P, et al. Central challenges facing the national clinical research enterprise. JAMA 2003;289(10):1278-1287.